

Sheet 1 of 2

FORM PTO-112		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: OC01625K		APPLICATION NO.: 10/665,005	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Kamil Paruch et al.			
				FILING DATE: 09/19/2003		GROUP: 1624	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	5,028,605 A	07/02/1991	Sablayrolles et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OR	AL	WO 02 060492 A	08/08/2002	WIPO	_____		
OR	AM	WO 02 50079 A	06/27/2002	WIPO	_____		
	AN						
	AO						
	AP						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
OR	AQ	Viste, O. et al., "Imidazo(1,2-a)pyrazine Derivatives with Brochodilatory and Cyclic Nucleotide Phosphodiesterase Inhibitory Activities", <i>Bioorganic & Med. Chem.</i> , 7: 1059-1065 (1999).					
OR	AR	K. Zurbonsen et al., "Antiproliferative effects of Imidazo[1,2- α]pyrazine Derivatives on the Dami Cell Line", <i>Biochemical Pharmacology</i> , 54: 365-371 (1997).					
OR	AS	K. Zurbonsen et al., "Apoptotic effects of Imidazo[1,2- α]pyrazine Derivatives in the Human Dami Line", <i>European Journal of Pharmacology</i> , 320: 215-221. (1997).					
	AT						
	AU						
	AV						
EXAMINER Dupont Rezz				DATE CONSIDERED 12/22/04			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Sheet 2 of 2

FORM PTO-1472		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: OC01625K		APPLICATION NO.: 10/665,005	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Kamil Paruch et al.			
				FILING DATE: 09/19/2003		GROUP: 1624	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AW						
	AX						
	AY						
	AZ						
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
<i>OR</i>	BH	WO 02/10162	02/07/2002	WIPO	_____	_____	
	BI						
	BJ						
	BK						
	BL						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>OR</i>	BM	A. Sanderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", <i>J. Clin. Oncology</i> , 16 : 2986-2999 (1998).					
<i>OR</i>	BN	J. Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem.</i> , 224 : 771-786 (1994).					
<i>OR</i>	BO	I. Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases cdc2, cdk2 and cdk5", <i>Eur. J. Biochem.</i> , 243 : 527-536 (1997).					
<i>OR</i>	BP	K. S. Kim et al., "Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities", <i>J. Medicinal Chemistry</i> , 45 : 3905-3927 (2002)					
	BQ						
	BR						
EXAMINER <i>Danpak Reng</i>				DATE CONSIDERED <i>12/22/04</i>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							